TriSalus Life Sciences, Inc. (TLSI) — Financial statements
Income statement, balance sheet, and cash flow for TriSalus Life Sciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 45↑53.4% | 29↑59.0% | 19↑49.3% | 12↑47.6% | 8 | |
| Cost of Revenue | 7↑69.8% | 4↑57.5% | 3↑15.4% | 2↑89.3% | 1 | |
| Gross Profit | 38↑50.8% | 25↑59.2% | 16↑56.9% | 10↑40.7% | 7 | |
| Operating Expenses | ||||||
| R&D Expenses | 15↓15.4% | 18↓40.7% | 30↑39.7% | 21↑50.2% | 14 | |
| General & Administrative Expenses | 21↑19.4% | 18↓23.6% | 24↑88.4% | 12↑42.6% | 9 | |
| Selling & Marketing Expenses | 29↑11.1% | 26↑51.7% | 17↑33.7% | 13↑54.2% | 8 | |
| SG&A Expenses | 50↑14.5% | 44↑8.0% | 41↑60.8% | 25↑48.2% | 17 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 65↑5.9% | 61↓12.6% | 70↑51.1% | 47↑49.1% | 31 | |
| Total Costs & Expenses | 72↑9.9% | 66↓10.1% | 73↑49.4% | 49↑50.6% | 32 | |
| Operating Results | ||||||
| Operating Income | -27↑25.5% | -36↑33.6% | -54↓49.5% | -36↓51.6% | -24 | |
| Depreciation & Amortization | 0.00↑100.0% | -3↓543.9% | 0.68↑65.2% | 0.41↓10.8% | 0.46 | |
| EBITDA | -27↑25.5% | -36↑38.3% | -59↓25.4% | -47↓98.4% | -24 | |
| EBIT | -27↑18.7% | -33↑44.2% | -59↓25.8% | -47↓96.3% | -24 | |
| Interest & Other Income | ||||||
| Net Interest Income | -5↓85.7% | -3↓747.2% | 0.42↑131.8% | 0.18↑110.2% | -2 | |
| Interest Income | 0.56↑37.4% | 0.40↓6.3% | 0.43↑139.4% | 0.18 | 0.00 | |
| Interest Expense | 6↑79.4% | 3↑19212.5% | 0.02↑1500.0% | 0.00↓99.9% | 2 | |
| Non-Operating Income | 0.00↑100.0% | -3↓162.4% | 5↓54.7% | 11 | 0.00 | |
| Other Income / Expenses | -12↓300.4% | 6↑225.6% | -5↑54.6% | -11↓123.3% | -5 | |
| Income Before Tax | -39↓30.6% | -30↑49.4% | -59↓25.8% | -47↓63.6% | -29 | |
| Income Tax Expense | 0.01↑16.7% | 0.01↓33.3% | 0.01↑0.0% | 0.01↑200.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -39↓30.6% | -30↑49.4% | -59↓25.8% | -47↓63.6% | -29 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -39↓18.0% | -33↑44.0% | -59↓25.8% | -47↓63.6% | -29 | |
| Bottom-Line Net Income | -70↓109.7% | -33↑47.7% | -64↓27.2% | -50↓73.4% | -29 | |
| EPS (Basic) | -1.84↓47.2% | -1.25↑43.9% | -2.23↓40.3% | -1.59↓72.8% | -0.92 | |
| EPS (Diluted) | -1.84↓47.2% | -1.25↑43.9% | -2.23↓40.3% | -1.59↓72.8% | -0.92 | |
| Weighted Average Shares | 38↑43.0% | 27↑0.1% | 26↓10.6% | 30↓5.3% | 31 | |
| Weighted Average Diluted Shares | 38↑43.0% | 27↑0.1% | 26↓10.6% | 30↓5.3% | 31 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.